Compare CWD & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWD | XAIR |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 10.1M |
| IPO Year | 2022 | 2015 |
| Metric | CWD | XAIR |
|---|---|---|
| Price | $1.22 | $0.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 86.7K | ★ 214.8K |
| Earning Date | 05-14-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.09 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,097,000.00 | $3,705,000.00 |
| Revenue This Year | N/A | $122.00 |
| Revenue Next Year | $19.17 | $58.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 219.67 |
| 52 Week Low | $0.20 | $0.15 |
| 52 Week High | $46.21 | $3.78 |
| Indicator | CWD | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 54.17 | 24.40 |
| Support Level | $1.15 | $0.15 |
| Resistance Level | $1.55 | $1.25 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 73.75 | 3.07 |
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.